Holen Sie sich die Stockscreener-App
8.50
5.26%
0.425
Schlusskurs vom Vortag:
$8.075
Offen:
$8.14
24-Stunden-Volumen:
2.45M
Relative Volume:
0.71
Marktkapitalisierung:
$880.43M
Einnahmen:
$45.97M
Nettoeinkommen (Verlust:
$-508.80M
KGV:
-1.5511
EPS:
-5.48
Netto-Cashflow:
$-382.65M
1W Leistung:
+4.68%
1M Leistung:
+23.91%
6M Leistung:
-39.16%
1J Leistung:
-67.52%
1-Tages-Spanne:
$8.025
$8.515
1-Wochen-Bereich:
$7.62
$8.89
52-Wochen-Spanne:
$5.90
$28.18
Intellia Therapeutics Inc Stock (NTLA) Company Profile
Firmenname
Intellia Therapeutics Inc
Sektor
Branche
Telefon
857-285-6200
Adresse
40 ERIE STREET, CAMBRIDGE, MA
Vergleichen Sie NTLA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NTLA
Intellia Therapeutics Inc
|
8.50 | 841.10M | 45.97M | -508.80M | -382.65M | -5.48 |
|
ONC
Beigene Ltd Adr
|
228.38 | 25.07B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.65 | 109.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.27 | 36.39M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
594.32 | 56.98B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
71.31 | 5.39B | 0 | -153.72M | -103.81M | -2.00 |
Intellia Therapeutics Inc Stock (NTLA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-21 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2025-03-05 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-02-28 | Herabstufung | Goldman | Neutral → Sell |
| 2025-02-28 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2025-01-27 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2024-02-23 | Herabstufung | Goldman | Buy → Neutral |
| 2024-02-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2023-04-13 | Eingeleitet | Canaccord Genuity | Buy |
| 2023-03-21 | Eingeleitet | Bernstein | Outperform |
| 2023-03-14 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2023-02-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-01-24 | Hochstufung | Citigroup | Sell → Neutral |
| 2023-01-19 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2022-10-11 | Eingeleitet | Morgan Stanley | Overweight |
| 2022-09-21 | Eingeleitet | JP Morgan | Overweight |
| 2022-09-01 | Eingeleitet | Citigroup | Sell |
| 2022-06-17 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2022-06-16 | Eingeleitet | BofA Securities | Buy |
| 2022-04-28 | Eingeleitet | Credit Suisse | Outperform |
| 2022-02-18 | Eingeleitet | William Blair | Outperform |
| 2022-02-07 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2022-01-31 | Eingeleitet | Cowen | Outperform |
| 2022-01-07 | Eingeleitet | Piper Sandler | Overweight |
| 2021-10-05 | Eingeleitet | Guggenheim | Buy |
| 2021-09-24 | Eingeleitet | Stifel | Buy |
| 2021-06-28 | Bestätigt | H.C. Wainwright | Buy |
| 2021-06-11 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-05-07 | Hochstufung | ROTH Capital | Neutral → Buy |
| 2021-05-04 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-03-04 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2020-12-22 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2020-10-27 | Eingeleitet | Truist | Buy |
| 2020-10-14 | Eingeleitet | Wells Fargo | Overweight |
| 2020-09-18 | Eingeleitet | Goldman | Buy |
| 2020-02-28 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2020-02-14 | Herabstufung | Wedbush | Outperform → Neutral |
| 2019-11-01 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2019-07-09 | Eingeleitet | Robert W. Baird | Outperform |
| 2019-06-10 | Eingeleitet | ROTH Capital | Neutral |
| 2019-05-03 | Hochstufung | Wedbush | Neutral → Outperform |
| 2019-04-12 | Eingeleitet | Evercore ISI | Outperform |
| 2018-11-02 | Herabstufung | Wedbush | Outperform → Neutral |
| 2018-10-29 | Eingeleitet | Credit Suisse | Neutral |
| 2018-09-21 | Eingeleitet | Raymond James | Mkt Perform |
| 2018-05-15 | Hochstufung | Chardan Capital Markets | Neutral → Buy |
| 2018-03-08 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2017-11-01 | Bestätigt | Jefferies | Buy |
| 2017-06-22 | Fortgesetzt | Jefferies | Buy |
| 2017-03-28 | Eingeleitet | Chardan Capital Markets | Buy |
| 2016-08-05 | Hochstufung | Jefferies | Hold → Buy |
Alle ansehen
Intellia Therapeutics Inc Aktie (NTLA) Neueste Nachrichten
Cathie Wood’s ARK Buys Intellia, Nextdoor, Sells Block Stock - Investing.com
Crispr Therapeutics Products 2025: Therapies, MOA Insights, - openPR.com
Wall Street Analysts See a 408.63% Upside in Intellia Therapeutics (NTLA): Can the Stock Really Move This High? - Yahoo Finance
Intellia Therapeutics (NASDAQ:NTLA) Shares Down 6.1% After Analyst Downgrade - Defense World
Transcript : Intellia Therapeutics, Inc. Presents at BofA Securities 2025 Healthcare Conference, May-13-2025 04 - marketscreener.com
(NTLA) Technical Data - news.stocktradersdaily.com
Intellia Therapeutics (NASDAQ:NTLA) Price Target Cut to $45.00 by Analysts at Guggenheim - Defense World
Forecasting The Future: 11 Analyst Projections For Intellia Therapeutics - Benzinga
Guggenheim Maintains 'Buy' Rating on NTLA, Lowers Price Target | - GuruFocus
Intellia Therapeutics Shares Have Struggled, But It's Now Go-Time (Rating Upgrade) - Seeking Alpha
Guggenheim cuts Intellia stock price target to $45, maintains buy By Investing.com - Investing.com India
Intellia Therapeutics (NTLA) Price Target Cut to $45 by Guggenhe - GuruFocus
Intellia Therapeutics Inc (NASDAQ: NTLA) – An Analysis Is What You Need - Stocksregister
Intellia Therapeutics’ (NTLA) Buy Rating Reiterated at Chardan Capital - Defense World
Analysts Have Made A Financial Statement On Intellia Therapeutics, Inc.'s (NASDAQ:NTLA) First-Quarter Report - simplywall.st
Analyst Estimates: Here's What Brokers Think Of Intellia Therapeutics, Inc. (NASDAQ:NTLA) After Its First-Quarter Report - Yahoo Finance
Industry Analysts Just Made An Upgrade To Their Intellia Therapeutics, Inc. (NASDAQ:NTLA) Revenue Forecasts - simplywall.st
News Flash: Analysts Just Made An Upgrade To Their Intellia Therapeutics, Inc. (NASDAQ:NTLA) Forecasts - Yahoo Finance
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Q1 2025 Earnings Call Transcript - Insider Monkey
Intellia's Q1 Loss Narrower Than Expected, Pipeline in Focus, Stock Up - TradingView
Truist Securities Cuts Price Target on Intellia Therapeutics to $33 From $50, Maintains Buy Rating - marketscreener.com
Intellia Therapeutics Inc (NTLA) Q1 2025 Earnings Call Highlights: Strategic Advancements Amid Revenue Decline - GuruFocus
Intellia Therapeutics Inc (NTLA) Q1 2025 Earnings Call Highlights: Strategic Advancements Amid ... - Yahoo Finance
Intellia Therapeutics Reports Q1 2025 Progress and Financials - TipRanks
Transcript : Intellia Therapeutics, Inc., Q1 2025 Earnings Call, May 08, 2025 - marketscreener.com
Intellia Therapeutics (NTLA) Price Target Reduced Amid Market Challenges | NTLA Stock News - GuruFocus
Intellia Therapeutics (NTLA) Advances in 2025 with Key Milestones - GuruFocus
Earnings call transcript: Intellia Therapeutics beats EPS and revenue forecasts in Q1 2025 - Investing.com
Intellia Therapeutics, Inc. (NTLA) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
Intellia Therapeutics Inc earnings beat by $0.17, revenue topped estimates - Investing.com
NTLA Financial Outlook: Cash Reserves and Future Funding | NTLA Stock News - GuruFocus
Intellia (NTLA) Surpasses Revenue Expectations and Advances Clinical Programs | NTLA Stock News - GuruFocus
Intellia Therapeutics (NTLA) Q1 2025 Earnings: EPS of -$1.10 Beats Estimates, Revenue Surpasses Expectations at $16.6 Million - GuruFocus
Intellia Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Company Progress | NTLA Stock News - GuruFocus
Intellia Therapeutics Reports Progress in Phase 3 Trials for Hereditary Angioedema and ATTR Amyloidosis, Highlights Financials for Q1 2025 - Nasdaq
Intellia Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Company Progress - GlobeNewswire
Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Gene Editing Leader Intellia Therapeutics Expands Team with 69,600 Share Inducement Grant - Stock Titan
Long-Term Investors in shares of Intellia Therapeutics, Inc. - openPR.com
Angioedema Clinical Trial Pipeline Analysis Demonstrates 15+ Key Companies at the Horizon Expected to Transform the Treatment Paradigm, Assesses DelveInsight - GlobeNewswire Inc.
Genome Editing Market Future Business Opportunities 2025-2032 - openPR.com
Genome Engineering Market Generated Opportunities, Future - openPR.com
(NTLA) Long Term Investment Analysis - news.stocktradersdaily.com
Intellia Therapeutics Inc (NTLA) Has Recovered 31.71% From Its Low: Is This The Beginning Of A Trend? - Stocksregister
Intellia Therapeutics Inc [NTLA] Records 200-Day SMA of $15.05 - knoxdaily.com
Earnings Preview: Intellia Therapeutics, Inc. (NTLA) Q1 Earnings Expected to Decline - Yahoo Finance
Intellia Therapeutics, Inc. (NTLA) Recently Broke Out Above the 50-Day Moving Average - Yahoo Finance
Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2025 Earnings and Company Updates - The Manila Times
Leading CRISPR Pioneer Intellia Therapeutics to Reveal Q1 2025 Financial Results and Pipeline Updates - Stock Titan
The growth track for Intellia Therapeutics Inc (NTLA) has changed recently - Sete News
Company’s Banking Stock: Dissecting a -16.35% Quarterly Revenue Decline Amid Growth - investchronicle.com
Finanzdaten der Intellia Therapeutics Inc-Aktie (NTLA)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.54%
7.58%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):